Global Dry Eye Treatment Devices Market is valued at approximately USD 223.0 million in 2021 and is anticipated to grow with a healthy growth rate of more than 7.6% over the forecast period 2022-2029. Dry eye is an ocular condition that affects tear film and ocular surface, which leads to irritation, insufficient lubrication, and inflammation of the eye. The primary factors attributing to the market growth are the rising prevalence of dry eye syndrome, the increasing number of contact lens wearers, and the rising inclination toward faster and non-invasive treatment approaches.
According to Statista, in 2018, the value of the worldwide dry eye syndrome market was estimated to account for USD 3.5 billion, which is anticipated to reach USD 5.1 billion by 2024. Therefore, the rising incidences of dry eye syndrome are propelling the market demand across the globe. In addition, the rising usage of visual display terminals, as well as surging demand for dry eye treatment technology in ophthalmic centers, are creating lucrative opportunities for market growth over the forecasting years. However, the presence of several contraindications pertaining to intense pulsed light and the availability of alternative treatment options are hindering market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Dry Eye Treatment Devices Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the rising incidences of Dry Eye Diseases (DED) and the presence of advanced healthcare services. Whereas, the Asia Pacific is expected to grow with the highest growth rate during the forecast period. Factors such as the high prevalence of dry eye disease, the increasing geriatric population, as well as growing demand for technologically advanced devices, are burgeoning the market growth in the forecasting years.
Major market players included in this report are:
MiBo Medical Group
Johnson & Johnson Vision Care
Recent Developments in the Market:
In May 2020, Alcon announced the launch of "No Reason to Wait: Success Starts Now"- an awareness program, which aims to educate professionals and patients about the significance and assistance of treating the root cause of Meibomian Gland Dysfunction (MGD). Thus, it is expected to fuel the commercial sale of the company's dry eye treatment devices including iLux and Systane.
In March 2021, Baring Private Equity Asia- a private investment firm, announced the acquisition of Lumenis's surgical business with USD 1.07 billion, which aims on holding the rights to Lumenis' international aesthetics and ophthalmology businesses.
Global Dry Eye Treatment Devices Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Technology, End-User, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study.
The report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
Broadband light (BBL)
Intense Pulsed Light (IPL)
Meibomian Gland Expression (MGX)
Rest of the World